ライフサイエンスコーパス: treatment-resistant

1 een subjects with DSM-IV bipolar depression (treatment-resistant).

2 -step treatment for those whose symptoms are treatment resistant.

3 vere form of the disorder that is frequently treatment resistant.

4 the patients, or their illnesses' being more treatment resistant.

5 f melanoma cells, which are slow-cycling and treatment-resistant.

6 Continued treatment for depression among treatment-resistant adolescents results in remission in

7 ure T cell cancers are typically aggressive, treatment resistant and associated with poor prognosis.

8 ccompanied by cognitive impairments that are treatment resistant and crucial to functional outcome.

9 m for solid tumors because hypoxic cells are treatment-resistant and more aggressive.

10 is were assessed to test the hypothesis that treatment-resistant and non-refractory patients would ex

11 Replicated differences between treatment-resistant and treatment-responsive patients in

12 uencies of the DRB1 alleles in patients with treatment-resistant arthritis, but the binding of hLFA-1

13 CEACAM6 may contribute to the pathology of treatment-resistant asthma via neutrophil and airway epi

14 tment strategies in specific forms of severe treatment-resistant asthma.

15 se with difficult-to-treat asthma and severe treatment-resistant asthma.

16 ; thus, they may facilitate the formation of treatment-resistant biofilm on indwelling plastic device

17 st randomized trial of competing options for treatment-resistant bipolar depression and assesses the

18 inicians as the most effective treatment for treatment-resistant bipolar depression, but no randomize

19 In patients with treatment-resistant bipolar depression, robust and rapid

20 algorithm-based pharmacological treatment in treatment-resistant bipolar depression.

21 apid antidepressant effects in patients with treatment-resistant bipolar depression.

22 ior to inositol and risperidone in improving treatment-resistant bipolar depression.

23 evidence-based options for the management of treatment-resistant bipolar depression.

24 nd antidepressant efficacy of pramipexole in treatment-resistant bipolar depression.

25 depression and electroconvulsive therapy for treatment-resistant bipolar disorder.

26 Glioblastoma multiforme is the most treatment-resistant brain tumor.

27 d SPAK expression in metastatic prostate and treatment-resistant breast cancers, suggesting that its

28 Presence of treatment-resistant cancer stem cells (CSC) may associat

29 The existence of treatment-resistant cancer stem cells contributes to the

30 Patients with metastatic and treatment-resistant cancer were prospectively enrolled a

31 ad and neck (SCCHN) is a common, aggressive, treatment-resistant cancer with a high recurrence rate a

32 uroleptics and neuromodulatory approaches in treatment-resistant cases provides alternatives for pati

33 f pathogenic autoantibodies, particularly in treatment-resistant cases.

34 nd suggest a unique therapeutic approach for treatment-resistant CCNE1-amplified tumors.

35 y and molecular basis for this 'alternative' treatment-resistant cell state remain incompletely under

36 eplete tumors of their tumor-propagating and treatment-resistant cell subpopulations.

37 Examples of putative treatment-resistant cells isolated in small topographica

38 rs with > 5% increase after therapy) suggest treatment-resistant cells, present in some LumA tumors,

39 we present these nonmedication approaches to treatment-resistant childhood epilepsy, with attention t

40 , double-blind, placebo-controlled study, 60 treatment-resistant children and adolescents (mean age=1

41 ssors increases the likelihood of developing treatment-resistant, chronic psychological problems, inc

42 acking clonal evolution and the emergence of treatment-resistant clones.

43 eater likelihood of depression classified as treatment resistant compared with depression classified

44 upporting the use of antitussives in chronic treatment-resistant cough.

45 rectal tissues collected from patients with treatment-resistant Crohn's disease who participated in

46 reatment-responsive CTCL versus higher-stage/treatment-resistant CTCL.

47 ccurrence of suicidal events, in a sample of treatment-resistant depressed adolescents.

48 nt response after ketamine administration in treatment-resistant depressed patients suggests a possib

49 Nineteen treatment-resistant depressed patients, 53% of whom were

50 ine produces rapid antidepressant actions in treatment-resistant depressed patients.

51 Forty treatment-resistant depressed unipolar patients with Ham

52 fy predictors of self-harm adverse events in treatment-resistant, depressed adolescents during the fi

53 recruited 469 patients aged 18-75 years with treatment resistant depression (on antidepressants for >

54 rmacotherapy) for primary care patients with treatment resistant depression compared with usual care

55 Eligible patients were aged 18-65 years with treatment-resistant depression (Hamilton Depression Rati

56 ion for adults aged older than 60 years with treatment-resistant depression (Montgomery Asberg Depres

57 ed in severe psychiatric conditions, such as treatment-resistant depression (TRD) and intractable obs

58 ticity and reduces cognitive difficulties in treatment-resistant depression (TRD) and remitted BD.

59 Patients with treatment-resistant depression (TRD) do not respond suff

60 stimulation (DBS) as a putative approach for treatment-resistant depression (TRD) has now been resear

61 essed prevention of relapse in patients with treatment-resistant depression (TRD) taking olanzapine/f

62 atter (SCC) may be an effective approach for treatment-resistant depression (TRD) that otherwise fail

63 l trials of deep brain stimulation (DBS) for treatment-resistant depression (TRD), including those ta

64 cs and innovative treatments--especially for treatment-resistant depression (TRD)--are essential.

65 5-HTP can confer antidepressant response in treatment-resistant depression (TRD).

66 apid antidepressant effects in patients with treatment-resistant depression (TRD).

67 eases, so we assessed their association with treatment-resistant depression (TRD).

68 ment with psilocybin (serotonin agonist) for treatment-resistant depression (TRD).

69 not respond to conventional ADs and develop treatment-resistant depression (TRD).

70 e intravenous (IV) infusion in patients with treatment-resistant depression (TRD).

71 rapy (MST) is a novel therapeutic option for treatment-resistant depression (TRD).

72 apid antidepressant effects in patients with treatment-resistant depression (TRD); however, the poten

73 val of vagus nerve stimulation for recurrent treatment-resistant depression and a pending considerati

74 or the safety and efficacy of psilocybin for treatment-resistant depression and motivates further tri

75 he dose-related efficacy of R/S-ketamine for treatment-resistant depression and the first to characte

76 subcallosal cingulate DBS as a treatment for treatment-resistant depression but did not show statisti

77 gonism does not have generalized efficacy in treatment-resistant depression but may improve depressiv

78 n current evidence, ketamine use for severe, treatment-resistant depression does not violate ethical

79 ressant effects of ketamine in patients with treatment-resistant depression drawn from a Chinese popu

80 stimulation implantation surgery for chronic treatment-resistant depression in a randomized and blind

81 tive antipsychotic medication to placebo for treatment-resistant depression in adults.

82 therefore is not an option for patients with treatment-resistant depression in routine clinical pract

83 Treatment-resistant depression is a significant public h

84 ce from recent clinical trials suggests that treatment-resistant depression may be associated with a

85 erformance indicates which older adults with treatment-resistant depression may respond favorably to

86 s been successfully applied to patients with treatment-resistant depression or in minimally conscious

87 target-based neuromodulation strategies for treatment-resistant depression patients.

88 The Treatment-Resistant Depression Registry investigated whe

89 f >/=18 and a Massachusetts General Hospital Treatment-Resistant Depression staging score of 2-10) an

90 Participants with treatment-resistant depression were implanted with a DBS

91 -blind study, adults (ages 18-64 years) with treatment-resistant depression were randomized to receiv

92 erior mid-cingulate cortex, 20 patients with treatment-resistant depression who had not received surg

93 d 94 volunteers, comprising 15 patients with treatment-resistant depression who had received bilatera

94 ver tranylcypromine for patients with highly treatment-resistant depression who have not benefited ad

95 y representative population of patients with treatment-resistant depression within the NHS and theref

96 To test the safety and efficacy of DBS for treatment-resistant depression, a prospective, randomise

97 t naturalistic study of efficacy outcomes in treatment-resistant depression, and it provides addition

98 patients with major depressive disorder have treatment-resistant depression, defined as no adequate r

99 To date, 163 patients, primarily with treatment-resistant depression, have participated in cas

100 Trials recruiting participants with treatment-resistant depression, treatment duration of le

101 highlight EPO as an interesting compound for treatment-resistant depression, which deserves further i

102 r imaging, were acquired in 16 patients with treatment-resistant depression, who then received SCC DB

103 ion of contacts in long-term stimulation for treatment-resistant depression.

104 potent antidepressant effects of ketamine in treatment-resistant depression.

105 d included 73 bipolar disorder patients with treatment-resistant depression.

106 id antidepressant responses in patients with treatment-resistant depression.

107 f the reward system in DBS for patients with treatment-resistant depression.

108 binant human EPO improves mood and memory in treatment-resistant depression.

109 apid antidepressant effects in patients with treatment-resistant depression.

110 a Phase II clinical development program for treatment-resistant depression.

111 ts are insufficient for clinical response in treatment-resistant depression.

112 oves depressive symptoms in individuals with treatment-resistant depression.

113 rapid-acting antidepressant in patients with treatment-resistant depression.

114 rs, is an important treatment for severe and treatment-resistant depression.

115 n surgical targeting in 11 participants with treatment-resistant depression.

116 ations in off-label ketamine use for severe, treatment-resistant depression.

117 tial antidepressant effects in patients with treatment-resistant depression.

118 cacy of psilocybin in patients with unipolar treatment-resistant depression.

119 over 3-5 years in primary care patients with treatment-resistant depression.

120 onset antidepressant effect in patients with treatment-resistant depression.

121 nically relevant population of patients with treatment-resistant depression.

122 Hepatitis C is a treatment-resistant disease affecting millions of people

123 would also specifically target the typically treatment-resistant disease associated with TP53 mutatio

124 redict treatment resistance, suggesting that treatment-resistant disease might be a distinct subtype

125 early 10% of people with asthma have severe, treatment-resistant disease, which is frequently associa

126 e extensive medical therapy and some develop treatment-resistant disease.

127 p53 function is often impaired in relapsed, treatment-resistant disease.

128 ability, abnormal neurological findings, and treatment-resistant epilepsy (in two of four).

129 ) with severe, intractable, childhood-onset, treatment-resistant epilepsy, who were receiving stable

130 tory intracranial hypertension and to manage treatment-resistant epilepsy.

131 mains a standard of therapy in patients with treatment-resistant epilepsy.

132 ile in children and young adults with highly treatment-resistant epilepsy.

133 fficacious in children and young adults with treatment-resistant epilepsy.

134 psy can also be appreciated in patients with treatment-resistant focal epilepsy who are treated with

135 pared with placebo as adjunctive therapy for treatment-resistant focal-onset seizures in tuberous scl

136 ost a third of patients with epilepsy have a treatment-resistant form, which is associated with sever

137 to study the biological mechanism underlying treatment-resistant forms of affective disorders.

138 hamartomas (HHs) are highly associated with treatment-resistant gelastic seizures.

139 Gliomas contain a small number of treatment-resistant glioma stem cells (GSCs), and it is

140 for depression and anxiety in traditionally treatment-resistant groups, including AN.

141 ST2 values were 2.3 times as likely to have treatment-resistant GVHD (95% confidence interval [CI],

142 rmine the association of this biomarker with treatment-resistant GVHD and 6-month mortality after tre

143 splantation improved risk stratification for treatment-resistant GVHD and death without relapse after

144 fter exclusions, 151 patients with advanced, treatment-resistant head and neck tumors, including squa

145 fter exclusions, 151 patients with advanced, treatment-resistant head and neck tumors, including squa

146 T imaging in treatment-sensitive COLO205 and treatment-resistant HT29 human colorectal cancer xenogra

147 T imaging in treatment-sensitive COLO205 and treatment-resistant HT29 human colorectal cancer xenogra

148 tures the BCR characteristics of aggressive, treatment-resistant human B-CLL.

149 en considered one of the most aggressive and treatment-resistant human cancers.

150 py, are used in clinical practice for severe treatment resistant hypertension in some countries.

151 h cardiovascular risk, in patients with true-treatment resistant hypertension, whereas it only affect

152 (Renal Denervation in Treatment Resistant Hypertension; NCT01687725).

153 ood pressure >/=140/>/=90 mm Hg and apparent treatment-resistant hypertension (aTRH) when subjects re

154 study, there were 54 patients with moderate treatment-resistant hypertension (office BP >/=140/90 mm

155 of renal denervation (RDN) in patients with treatment-resistant hypertension according to the establ

156 ut not the efficacy of renal denervation for treatment-resistant hypertension at 6 months post proced

157 PDE5Is might also benefit patients with treatment-resistant hypertension, preeclampsia, or perip

158 after RDN persist long term in patients with treatment-resistant hypertension, with good safety.

159 n muscle glucose metabolism in patients with treatment-resistant hypertension.

160 ally reduces blood pressure in patients with treatment-resistant hypertension.

161 y BP substantially in patients with moderate treatment-resistant hypertension.

162 e A antagonist, darusentan, in patients with treatment-resistant hypertension.

163 (cer) striatal values than did patients with treatment-resistant illness (effect size=1.11) and healt

164 ignificant differences between patients with treatment-resistant illness and healthy volunteers in th

165 Compared with non-refractory patients, treatment-resistant individuals exhibited reduced connec

166 ostriatal connectivity was more pervasive in treatment-resistant individuals.

167 notherapy; however, some subjects experience treatment-resistant inflammation or adverse reactions to

168 uld be an effective therapy for extensive or treatment-resistant Kaposi sarcoma.

169 Remission of treatment-resistant late-life depression (defined as a M

170 of aripiprazole augmentation for first-line treatment-resistant late-life depression (Incomplete Res

171 phorylation, a process that is suppressed in treatment-resistant leukemic cells.

172 a and 1b) is responsible for the majority of treatment-resistant liver disease worldwide.

173 Treatment-resistant Lyme arthritis (TRLA) develops in 10

174 Odds ratios (ORs) for the presence of 1 or 2 treatment-resistant Lyme arthritis alleles were 0.8 (95%

175 Treatment-resistant Lyme arthritis alleles were not foun

176 Coincidentally, patients with chronic, treatment-resistant Lyme arthritis develop an immune res

177 Treatment-resistant Lyme arthritis occurs in a subset of

178 Treatment-resistant Lyme arthritis patients' T cells, cl

179 putative autoantigen in chronic, antibiotic treatment-resistant Lyme arthritis.

180 he critical epitope in triggering antibiotic treatment-resistant Lyme arthritis.

181 cies of the 5 MHC molecules in patients with treatment-resistant Lyme arthritis.

182 esion may be critical in the pathogenesis of treatment-resistant Lyme arthritis.

183 evious report including 10 participants with treatment-resistant major depression (TRD) found that si

184 apid antidepressant effects in patients with treatment-resistant major depression (TRD); these effect

185 Patients with treatment-resistant major depression experiencing a majo

186 Treatment-resistant major depression is common and poten

187 ix women) with moderate-to-severe, unipolar, treatment-resistant major depression received two oral d

188 venlafaxine and mirtazapine in patients with treatment-resistant major depression whose current depre

189 rapid and prolonged antidepressant effect in treatment-resistant major depression.

190 f ketamine in a large group of patients with treatment-resistant major depression.

191 lation strategy, deep brain stimulation, for treatment-resistant major depression.

192 apid antidepressant effects in subjects with treatment-resistant major depressive disorder (MDD).

193 uropsychological outcome of 25 patients with treatment-resistant major depressive disorder (TRD) who

194 e imaging study with 40 patients with highly treatment-resistant major depressive disorder and never-

195 Primary outcome criterion was severity of treatment-resistant major depressive disorder as assesse

196 Treatment-resistant major depressive disorder is a preva

197 L-6 in two separate cohorts of patients with treatment-resistant major depressive disorder.

198 bundle may significantly reduce symptoms in treatment-resistant major depressive disorder.

199 enal cell carcinoma (RCC) is one of the most treatment-resistant malignancies in humans.

200 lular carcinoma (HCC) is a highly prevalent, treatment-resistant malignancy with a multifaceted molec

201 Although melanoma is a historically treatment-resistant malignancy, in recent years unpreced

202 fic T cells is not restricted to chronic and treatment-resistant manifestations.

203 Twenty-eight medication-free inpatients with treatment-resistant MDD and 16 healthy controls (HCs) pa

204 bo-controlled study, 22 subjects with DSM-IV treatment-resistant MDD received a single infusion of ei

205 ugh preliminary, these results indicate that treatment-resistant MDD subjects showed decreased metabo

206 nary study, 20 unmedicated participants with treatment-resistant MDD underwent positron emission tomo

207 In patients with treatment-resistant MDD, a single intravenous dose of th

208 0RSK inhibition as a therapeutic strategy in treatment-resistant melanoma and provide insight into th

209 We analyzed the primary tumor, the sole treatment-resistant metastasis, and germline tissue to e

210 Preliminary evidence of activity in treatment-resistant metastatic breast cancer requires co

211 matergic modulator ketamine are effective in treatment-resistant mood disorders, underscoring the pot

212 dels, with highly glycolytic tumors becoming treatment resistant more rapidly than poorly glycolytic

213 erful surgical therapy for the management of treatment-resistant movement disorders, epilepsy and neu

214 rd detection thresholds, frequently harbored treatment-resistant mutations, and were more common in s

215 ositis account for some cases of apparently "treatment-resistant" myositis.

216 medication (n=9); or (2) treatment response: treatment resistant (n=5) or treatment responsive (n=4).

217 th and survival behavior of this notoriously treatment-resistant neoplasm.

218 treal aflibercept is effective in previously treatment-resistant neovascular AMD.

219 ation for the clinically important, profound treatment-resistant neuromuscular paralysis seen in huma

220 apy for well-screened patients with specific treatment-resistant neuropsychiatric diseases.

221 our activity in patients with progressive or treatment-resistant NSCLC, providing a rationale for fur

222 fective therapeutic avenue for patients with treatment-resistant obsessive-compulsive disorder (OCD).

223 , as an adjunctive therapy for children with treatment-resistant OCD.

224 stimulation, and neurosurgical ablation for treatment-resistant OCD.

225 ent (escitalopram: 20 mg per 12 weeks) in 11 treatment-resistant older adults with major depression;

226 excluded studies that focused exclusively on treatment-resistant patient populations defined within t

227 duced significant blood pressure lowering in treatment-resistant patients at 6 months after the proce

228 ed for symptom severity levels by recruiting treatment-resistant patients currently showed low sympto

229 ntify all neuroimaging studies that examined treatment-resistant patients or longitudinally assessed

230 However, in this study, the treatment-resistant patients were highly symptomatic, wh

231 apid and prolonged antidepressant effects in treatment-resistant patients with major depressive disor

232 schach protocols for 90 seriously disturbed, treatment-resistant patients, 42 of whom were primarily

233 ologic medications are increasingly given to treatment-resistant patients, but they can represent hig

234 In addition, among treatment-resistant patients, new mutations were acquire

235 s that could be therapeutically exploited in treatment-resistant patients.

236 ely sustained antidepressant action, even in treatment-resistant patients.

237 ntidepressant drugs and reduce the number of treatment-resistant patients.

238 asts up to 2 weeks, and is effective even in treatment-resistant patients.

239 erotonin reuptake inhibitors (SSRIs) in some treatment-resistant patients; however, it is not known w

240 Of note, treatment-resistant plasma cells contained a substantial

241 positively correlated with the frequency of treatment-resistant plasma cells in the bone marrow.

242 The majority targeted treatment resistant positive symptoms.

243 growth of AR-positive, but not AR-negative, treatment-resistant prostate cancer cells.

244 ss of compounds with the potential to combat treatment-resistant prostate cancer.

245 deep brain stimulation in four patients with treatment-resistant psychiatric disease.

246 ia, continuous rapid cycling, psychosis, and treatment-resistant psychopathology.

247 -year-old woman with persistent, unilateral, treatment-resistant pulsatile tinnitus caused by a small

248 detection and phenotypic characterization of treatment-resistant residual disease.

249 for ameliorating psychosis in patients with treatment-resistant schizophrenia (TRS), for reduction o

250 ation-based cohort of 2,370 individuals with treatment-resistant schizophrenia after Jan.

251 A total of 33 patients with treatment-resistant schizophrenia and 31 healthy control

252 s that a different neurobiology may underlie treatment-resistant schizophrenia and that dopamine synt

253 Identification of patients at high risk of treatment-resistant schizophrenia at the time of schizop

254 induced by drug withdrawal in patients with treatment-resistant schizophrenia did not impede subsequ

255 Up to 70% of patients with treatment-resistant schizophrenia do not respond to cloz

256 ients fulfilled the main proxy definition of treatment-resistant schizophrenia during a median follow

257 Patients with treatment-resistant schizophrenia had an excess of rare

258 Fifty patients with treatment-resistant schizophrenia hospitalized on a rese

259 antipsychotic among adults with evidence of treatment-resistant schizophrenia in routine clinical pr

260 some of the neurobiological changes seen in treatment-resistant schizophrenia lie along a continuum

261 higher mortality rate among individuals with treatment-resistant schizophrenia not treated with cloza

262 The prevalence of treatment-resistant schizophrenia points to a discrete i

263 We used a treatment-based proxy for treatment-resistant schizophrenia to identify candidate

264 Our main proxy definition of treatment-resistant schizophrenia was the earliest insta

265 chotic is more efficacious for patients with treatment-resistant schizophrenia, and blinded RCTs-in c

266 In treatment-resistant schizophrenia, clozapine is consider

267 Twelve patients with treatment-resistant schizophrenia, twelve patients with

268 with clozapine treatment in individuals with treatment-resistant schizophrenia.

269 sitive or negative symptoms in patients with treatment-resistant schizophrenia.

270 d to have superior efficacy in patients with treatment-resistant schizophrenia.

271 clozapine with risperidone in patients with treatment-resistant schizophrenia.

272 antipsychotic treatments and this is termed treatment-resistant schizophrenia.

273 ity was significantly lower in patients with treatment-resistant schizophrenia.

274 be included in future prediction models for treatment-resistant schizophrenia.

275 .39]) were all significantly associated with treatment-resistant schizophrenia.

276 65 years with tuberous sclerosis complex and treatment-resistant seizures (>/=16 in an 8-week baselin

277 patients with tuberous sclerosis complex and treatment-resistant seizures.

278 of medical therapy, but 2 patients developed treatment-resistant SLE, and we decided to pursue treatm

279 in the induction and/or maintenance of this treatment-resistant state.

280 1)R mechanisms may have an essential role in treatment-resistant stimulant abuse, suggesting new appr

281 our entire research population, but also in treatment-resistant subgroups and subgroups with a histo

282 Treatment-resistant subjects had significantly higher TH

283 Eighty treatment-resistant subjects who met DSM-IV criteria for

284 of glioblastoma (GBM) is driven in part by a treatment-resistant subpopulation of GBM stem cells (GSC

285 tion was significantly stronger than that in treatment-resistant SZ subjects or in NCs.

286 (NCs, n=13) vs subjects with SZ (n=25); NC, treatment-resistant SZ, and treatment-responsive SZ; and

287 Treatment-resistant (TR) ER+ cell lines (MCF-7:5C and MC

288 line, which was isolated from an aggressive, treatment-resistant triple-negative breast cancer that d

289 Genomically, the treatment-resistant tumor uniquely harbored biallelic PT

290 The majority of advanced, treatment-resistant tumors across tumor types harbor bio

291 sion of TRIP13 in SCCHN leads to aggressive, treatment-resistant tumors and enhanced repair of DNA da

292 In the treatment-resistant tumors we noted the emergence of CD3

293 es as well as contribute to the evolution of treatment-resistant tumour cells.

294 loidosis should be considered in atypical or treatment resistant, upper or lower chronic gastrointest

295 tify the evolutionary dynamics of these post-treatment resistant variant populations.

296 After failure to achieve SVR with TVR-based treatment, resistant variants are observed in most patie

297 ociated antigens, which reduces emergence of treatment-resistant variants and also permits rational,

298 ive antiviral strategy to avoid selection of treatment-resistant variants, and inhibitors of autophag

299 g therapy also may be successful in cases of treatment-resistant vasculitis.

300 longed lamivudine therapy is associated with treatment-resistant YMDD mutant hepatitis B virus (HBV).